Biology:FCE-28260
From HandWiki
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Identifiers | |
| |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C28H35F3N2O2 |
| Molar mass | 488.58 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
FCE-28260 is an azasteroidal 5α-reductase inhibitor which was developed for the treatment of benign prostatic hyperplasia and androgenic alopecia (pattern hair loss) in the 1990s but was never marketed.[1][2] FCE-28260 has been found to inhibit rat and human 5α-reductase with half-maximal inhibitory concentrations (IC50) of 15 and 16 nM, respectively, while finasteride had values of 30 and 52 nM.[1]
References
- ↑ 1.0 1.1 Giudici, D.; Briatico, G.; Cominato, C.; Zaccheo, T.; Iehlè, C.; Nesi, M.; Panzeri, A.; Di Salle, E. (1996). "FCE 28260, a new 5 alpha-reductase inhibitor: In vitro and in vivo effects". The Journal of Steroid Biochemistry and Molecular Biology 58 (3): 299–305. doi:10.1016/0960-0760(96)00040-4. PMID 8836165.
- ↑ Salle Enrico Di, Marcella Nesi, Achille Panzeri, "Epimers of (22RS)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide", EP patent 0782582, published 1997-07-09.
 |
